WeTrials
Recruiting

A Multi-Arm, Open Label, Phase II Trial of WP1066 and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

What is this study?

This study is testing a new combination treatment of an experimental medication called WP1066 and standard radiation therapy for people with a newly diagnosed aggressive brain tumor called glioblastoma. Researchers hope this combined approach will better stop tumor growth and help patients live longer by tackling the cancer in two different ways.

Who can participate?

You may be able to join if you have a newly confirmed glioblastoma with specific genetic features, such as normal IDH genes and an unmethylated MGMT gene status. However, previous treatments like certain past medications, gene therapy, or using the Optune device may mean you cannot participate.

What will happen?

During the study, you will receive radiation therapy alongside the experimental drug WP1066, which is designed to block cancer growth. Your care team will also perform regular MRI scans, collect tissue or fluid samples, and possibly perform surgery as part of your monitoring and treatment plan.

Where and when?

This study is currently recruiting participants and takes place at medical centers in Chicago and Warrenville, Illinois.

Key Points
  • 1Tests the experimental drug WP1066 combined with radiation therapy for glioblastoma.
  • 2Requires specific genetic markers in your tumor, like normal IDH genes.
  • 3Involves regular MRI scans, sample collections, and monitoring by the study team.

Related video

Moleculin CEO: WP1066 plus radiation phase 2 trial update (2025)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Glioblastoma, IDH-WildtypeMGMT-Unmethylated Glioblastoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.